Opioids With Abuse-Deterrent

Purdue has been a leader in medical advancements for pain management and a pioneer in the research of opioids with abuse-deterrent properties. Purdue was the first company to introduce opioids with abuse-deterrent properties through development of novel formulations and abuse deterrence studies. Opioids with abuse-deterrent properties are not abuse proof and they do not prevent the risk of addiction, overdose, or death.

For more than 30 years, Purdue has developed prescription opioid analgesics to alleviate the pain experienced by millions of people. As a pharmaceutical leader in pain medicine, we are acutely aware of the public health risks these powerful medications create, especially when they are diverted, misused, and/or abused. That’s why we work with health experts, law enforcement, and government agencies on efforts to reduce the risks of opioid abuse and misuse without reducing appropriate pain treatment. Opioids with abuse-deterrent properties won’t stop all prescription opioid abuse, but they one part of the comprehensive approach needed to address this complex public health issue.

The Importance of Developing Formulations With Abuse-Deterrent Properties

The U.S. Food and Drug Administration (FDA) cites the development of opioids with abuse-deterrent properties as one potentially important step in helping to deter prescription opioid abuse and misuse.1 The science of abuse deterrence is relatively new, and the formulation technologies and the analytical, clinical, and statistical methods for evaluating those technologies are rapidly evolving.1

The research and development of opioid analgesics with abuse-deterrent properties is intended to help deter the abuse, misuse, and diversion of these prescription pain medications—while ensuring that patients in pain continue to have appropriate access to these important therapies.1

Although there is no technology or formulation that can prevent all abuse of opioids, the availability of prescription opioids with abuse-deterrent properties is an important advancement toward the goal of providing responsible pain management for appropriate patients.1


  1. US Food and Drug Administration, Center for Drug Evaluation and Research (CDER). US Department of Health and Human Services. Guidance for Industry: Abuse-Deterrent Opioids—Evaluation and Labeling. Rockville, MD: US Food and Drug Administration; 2015.